GU CANCERS SYMPOSIUM 2024 ROUNDTABLE DISCUSSION: BRCAaway
OR
Chair
Dr. Nazanin Fallah-Rad
Panelists
Dr. Sebastien Hotte
Dr. Maria Jiang
This program has been made possible through unrestricted support from EMD Serono & Ipsen
Studies/trials discussed:
- BRCAaway Study
- BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) bearing homologous recombination-repair mutations (HRRm).
